Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. CRSP Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

CRISPR Therapeutics (CRSP)

Market Price (9/18/2025): $59.49 | Market Cap: $5.2 Bil
Sector: Health Care | Industry: Biotechnology

CRISPR Therapeutics (CRSP)

Market Price (9/18/2025): $59.49
Market Cap: $5.2 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29%		 Weak multi-year price returns
2Y Excs Rtn is -28%, 3Y Excs Rtn is -76%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -552 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1578%
1  Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13		 Expensive valuation multiples
P/SPrice/Sales ratio is 147x
2   Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -82%
3   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -928%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1002%
4   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14%
5   Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 25%
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29%
1 Weak multi-year price returns
2Y Excs Rtn is -28%, 3Y Excs Rtn is -76%
2 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -552 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1578%
4 Expensive valuation multiples
P/SPrice/Sales ratio is 147x
5 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -82%
6 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -928%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1002%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14%
8 Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 25%

Market Valuation

 9/18/252024202320222021
Share Price CYE$59.49$39.36$62.60$40.65$75.78
Market Cap CYE ($ Bil)5.23.45.03.25.8
Total Debt ($ Bil)0.20.20.20.20.2
Total Cash ($ Bil)1.71.91.71.82.4
Enterprise Value ($ Bil)3.73.65.23.46.0
Valuation Ratios     
P/S TTM148.094.913.47248.66.3
P/EBIT TTM-9.4-7.1-22.3-4.715.4
P/E TTM-11.1-9.1-32.3-4.915.2
Sector Ratios     
P/S TTM (Sector)3.83.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/18/2520242023
Share Price CYE$59.49$39.36$62.60
Market Cap CYE ($ Bil)5.23.45.0
Total Debt ($ Bil)0.20.20.2
Total Cash ($ Bil)1.71.91.7
Enterprise Value ($ Bil)3.73.65.2
Valuation Ratios   
P/S TTM148.094.913.4
P/EBIT TTM-9.4-7.1-22.3
P/E TTM-11.1-9.1-32.3
Sector Ratios   
P/S TTM (Sector)3.83.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
CRSP Return151%-51%-46%54%-37%50%-8%
Peers Return60%35%6%8%-6%13%159%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: NTLA, ABBV, AMGN, GILD, VRTX. See CRSP Returns vs. Peers.
[3] 2025 data is for the year up to 9/17/2025 (YTD)

Better Bets than CRISPR Therapeutics (CRSP)

 CRSPBetter Performance than CRSP
MetricValueIndustry (Biotechnology)
Rev Chg LTM-82.5%ABBV (6.1%), AMGN (12.9%), GILD (3.8%), VRTX (10.5%), REGN (5.4%)
Rev Chg 3Y Avg380.7%BBIO (1225.0%), AXSM (699.5%), CYTK (824.6%), TGTX (539.4%), ARWR (908.8%)
Op Mgn LTM-1578.5%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (27.0%)
CFO/Rev LTM-927.9%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (33.4%)
FCF/Rev LTM-1001.6%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (25.0%)
Total Yield-9.1%ABBV (3.9%), AMGN (7.8%), GILD (7.3%), VRTX (3.7%), REGN (7.5%)
 CRSPBetter Performance than CRSP
MetricValueAll Other Sectors
Rev Chg LTM-82.5%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg380.7%QXO (1115.2%), ENVX (436.9%), PFLT (12481.5%), URG (7785.9%), IVR (417.6%)
Op Mgn LTM-1578.5%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM-927.9%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM-1001.6%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield-9.1%NVDA (2.1%), MSFT (3.3%), AAPL (3.2%), GOOGL (4.1%), AMZN (2.9%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1CRSP Dip Buy Analysis  
2CRISPR Therapeutics Total Shareholder Return (TSR): -37.1% in 2024 and -19.6% 3-yr compounded annual returns (above peer average)  
3Day 6 of Gains Streak for CRISPR Therapeutics Stock with 35% Return (vs. 35% YTD) [2/20/2025]Notification 
4Day 5 of Gains Streak for CRISPR Therapeutics Stock with 33% Return (vs. 33% YTD) [2/19/2025]Notification 
5CRISPR Therapeutics (CRSP) Operating Cash Flow ComparisonFinancials 
6CRISPR Therapeutics (CRSP) Net Income ComparisonFinancials 
7CRISPR Therapeutics (CRSP) Operating Income ComparisonFinancials 
8CRISPR Therapeutics (CRSP) Revenue ComparisonFinancials 
9CRISPR Therapeutics vs. Coherus BioSciences: With Return Forecast Of 49%, CRISPR Therapeutics Is A Better BetPeer Comparison 
10CRISPR Therapeutics vs. Editas Medicine: With Return Forecast Of 49%, CRISPR Therapeutics Is A Better BetPeer Comparison 
11ARTICLES  
12Market Movers | Winners: TLN, CRSP, IVZ | Losers: SRPT, EVH, ENOV July 19th, 2025
13Up 24% In A Month, Will CRISPR Stock Continue To See Higher Levels? June 21st, 2022
14What’s Happening With CRISPR Stock? December 9th, 2021
15Gene Editing Stocks Lag On Clinical Setbacks, Rising Yields. Time To Buy? October 18th, 2021
16Will CRISPR Stock Rebound After A 17% Fall In A Month? October 12th, 2021
Title
0DASHBOARDS
1Market Movers | Winners: TLN, CRSP, IVZ | Losers: SRPT, EVH, ENOV
2Up 24% In A Month, Will CRISPR Stock Continue To See Higher Levels?
3What’s Happening With CRISPR Stock?
4Gene Editing Stocks Lag On Clinical Setbacks, Rising Yields. Time To Buy?
5Will CRISPR Stock Rebound After A 17% Fall In A Month?
6ARTICLES
7CRSP Dip Buy Analysis
8CRISPR Therapeutics Total Shareholder Return (TSR): -37.1% in 2024 and -19.6% 3-yr compounded annual returns (above peer average)
9Day 6 of Gains Streak for CRISPR Therapeutics Stock with 35% Return (vs. 35% YTD) [2/20/2025]
10Day 5 of Gains Streak for CRISPR Therapeutics Stock with 33% Return (vs. 33% YTD) [2/19/2025]
11CRISPR Therapeutics (CRSP) Operating Cash Flow Comparison
12CRISPR Therapeutics (CRSP) Net Income Comparison
13CRISPR Therapeutics (CRSP) Operating Income Comparison
14CRISPR Therapeutics (CRSP) Revenue Comparison
15CRISPR Therapeutics vs. Coherus BioSciences: With Return Forecast Of 49%, CRISPR Therapeutics Is A Better Bet
16CRISPR Therapeutics vs. Editas Medicine: With Return Forecast Of 49%, CRISPR Therapeutics Is A Better Bet

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11931.7%11931.7%
2GIBOGIBO10714.0% 
3LNZALanzaTech Global8455.2%-86.3%
4GTIGraphjet Technology3998.4%-93.1%
5GWAVGreenwave Technology Solutions3582.8%-91.4%
6QMMMQMMM3409.6%8153.1%
7ECDAECD Automotive Design2715.2%307.9%
8OESXOrion Energy Systems1373.7%14.2%
9OPOceanPal1266.5%-95.6%
10BCTXBriaCell Therapeutics1032.4%-89.8%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-94.5%-96.0%
2STFSStar Fashion Culture-92.3%-97.9%
3ELPWElong Power-91.1%-76.9%
4NXTTNext Technology-90.1%-95.4%
5EPIXESSA Pharma-89.4%-8.9%
6NAKAKindly MD-88.1% 
7BINIBollinger Innovations-87.6%-100.0%
8JEM707 Cayman-87.4%-98.2%
9YAASYouxin Technology-83.3%-98.4%
10NEONNeonode-82.5%-51.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for CRISPR Therapeutics

Financials

CRSPNTLAABBVAMGNGILDVRTXMedian
NameCRISPR T.Intellia.AbbVie Amgen Gilead S.Vertex P. 
Mkt Price59.0712.41220.81274.71112.26387.15166.53
Mkt Cap5.11.3390.4147.8139.899.4119.6
Rev LTM355358,32834,91728,86211,41920,140
Op Inc LTM-552-51213,6958,19210,797-1993,996
FCF LTM-351-42218,23910,6059,3693,5006,434
FCF 3Y Avg-280-39620,2738,5908,3971,9845,191
CFO LTM-325-41919,28312,0139,8683,8466,857
CFO 3Y Avg-263-38721,1549,7538,9492,3245,636

Growth & Margins

CRSPNTLAABBVAMGNGILDVRTXMedian
NameCRISPR T.Intellia.AbbVie Amgen Gilead S.Vertex P. 
Rev Chg LTM-82.5%15.0%6.1%12.9%3.8%10.5%8.3%
Rev Chg 3Y Avg380.7%6.2%0.6%10.0%1.6%11.0%8.1%
Rev Chg Q-104.8%6.6%9.4%1.8%12.1%9.4%
QoQ Delta Rev Chg LTM0.0%16.0%1.7%2.3%0.4%2.9%2.0%
Op Mgn LTM-1,578.5%-968.7%23.5%23.5%37.4%-1.7%10.9%
Op Mgn 3Y Avg-678.1%-991.9%27.2%26.4%39.2%26.5%26.5%
QoQ Delta Op Mgn LTM-223.0%218.7%1.0%1.6%-0.0%2.0%1.3%
CFO/Rev LTM-927.9%-791.9%33.1%34.4%34.2%33.7%33.4%
CFO/Rev 3Y Avg-396.8%-766.0%37.5%32.0%31.9%22.5%27.2%
FCF/Rev LTM-1,001.6%-798.0%31.3%30.4%32.5%30.6%30.5%
FCF/Rev 3Y Avg-426.2%-785.0%36.0%28.2%30.0%19.2%23.7%

Valuation

CRSPNTLAABBVAMGNGILDVRTXMedian
NameCRISPR T.Intellia.AbbVie Amgen Gilead S.Vertex P. 
Mkt Cap5.11.3390.4147.8139.899.4119.6
P/S146.924.46.74.24.88.77.7
P/EBIT-9.3-2.566.314.317.022.615.7
P/E-11.0-2.7103.722.322.127.322.2
P/CFO-15.8-3.120.212.314.225.813.2
Total Yield-9.1%-37.3%3.9%7.8%7.3%3.7%3.8%
Dividend Yield0.0%0.0%2.9%3.4%2.8%0.0%1.4%
FCF Yield 3Y Avg-6.4%-23.9%7.3%6.2%8.0%2.1%4.1%
D/E0.00.10.20.40.20.00.1
Net D/E-0.3-0.30.20.30.1-0.00.0

Returns

CRSPNTLAABBVAMGNGILDVRTXMedian
NameCRISPR T.Intellia.AbbVie Amgen Gilead S.Vertex P. 
1M Rtn2.6%15.7%6.9%-6.1%-4.2%-0.7%0.9%
3M Rtn33.0%29.3%20.1%-4.4%4.7%-13.7%12.4%
6M Rtn40.8%33.4%5.9%-11.5%5.9%-24.5%5.9%
12M Rtn18.4%-45.0%18.2%-14.7%39.2%-19.6%1.8%
3Y Rtn-16.2%-81.1%71.6%30.8%90.5%33.6%32.2%
1M Excs Rtn0.2%13.3%4.5%-8.5%-6.5%-3.0%-1.4%
3M Excs Rtn26.4%19.2%9.8%-14.8%-5.7%-22.7%2.0%
6M Excs Rtn26.6%17.5%-12.4%-29.9%-14.3%-42.0%-13.4%
12M Excs Rtn3.4%-61.1%0.4%-31.9%22.3%-37.6%-15.7%
3Y Excs Rtn-76.0%-141.5%13.2%-33.4%25.2%-28.7%-31.0%

Comparison Analyses

Title
0CRISPR Therapeutics vs. Coherus BioSciences: With Return Forecast Of 49%, CRISPR Therapeutics Is A Better Bet
1CRISPR Therapeutics vs. Editas Medicine: With Return Forecast Of 49%, CRISPR Therapeutics Is A Better Bet
2CRISPR Therapeutics vs. Sangamo Therapeutics: With Return Forecast Of 69%, Sangamo Therapeutics Is A Better Bet
3CRISPR Therapeutics vs. Intellia Therapeutics: With Return Forecast Of 49%, CRISPR Therapeutics Is A Better Bet
4CRISPR Therapeutics vs. Fate Therapeutics: With Return Forecast Of 74%, Fate Therapeutics Is A Better Bet
5CRISPR Therapeutics vs. BridgeBio Pharma: With Return Forecast Of 85%, BridgeBio Pharma Is A Better Bet
6CRISPR Therapeutics vs. NAPCO Security Technologies: With Return Forecast Of 46%, NAPCO Security Technologies Is A Better Bet
7CRISPR Therapeutics vs. Ambarella: Neither Seems Like A Good Bet
8CRISPR Therapeutics vs. Inter Parfums: With Return Forecast Of 56%, Inter Parfums Is A Better Bet
9CRISPR Therapeutics vs. Box: With Return Forecast Of 17%, Box Is A Better Bet

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/4/20255/6/20252/11/202511/5/20248/5/20245/8/20242/21/202411/6/20238/7/20235/8/20232/21/202311/1/2022
Key Financials Quarterly            
Total Revenue003500020007010000
Ebitda-225-144-60-105-146-13674-127-90-59-126-177
Operating Income-229-148-65-110-151-14170-132-95-64-132-182
Net Income-209-136-37-86-126-11789-112-78-53-111-175
EPS-2.40-1.58-0.44-1.01-1.49-1.431.13-1.41-0.98-0.67-1.41-2.24
Key Financials TTM            
Total Revenue TTM353535200200270370170170100013
Ebitda TTM-534-455-447-313-335-279-203-403-453-538-649-663
Operating Income TTM-552-474-467-332-355-299-223-424-474-562-673-687
Net Income TTM-468-386-366-240-266-217-154-354-416-524-650-681
Growth Rates Quarterly            
Total Revenue Growth---82.5%--100.0%-100.0%3333233.3%-100.0%44203.8%56079.8%-100.0%-71.4%
EBITDA Growth-53.5%-5.8%-180.2%17.3%-62.2%-128.4%159.3%28.1%48.7%65.0%9.9%-43.6%
Operating Income Growth-51.6%-5.6%-192.8%16.8%-58.8%-118.0%152.9%27.4%48.0%63.4%9.7%-41.6%
Net Income Growth-65.0%-16.6%-141.8%23.4%-62.6%-119.7%180.8%35.7%58.2%70.4%21.7%-37.3%
Margins Quarterly            
EBITDA Margin---170.7%---37.2%--128.9%-59.4%-2094916.7%-188691.5%
Operating Income Margin---184.5%---34.8%--136.0%-64.5%-2192350.0%-194029.8%
Net Income Margin---106.6%---44.7%--111.1%-53.1%-1842916.7%-185690.4%
Cash & Debt            
Total Cash1,7211,8551,9041,9362,0022,1081,6941,7401,7681,8831,8151,896
Total Debt215219224228231235239242245240244242
Net Debt / (Cash)-1,506-1,636-1,680-1,708-1,770-1,873-1,455-1,498-1,523-1,643-1,571-1,654
Cash Flows Quarterly            
FCF from Operations-114-54-50-107-96110-96-40-1339-113-105
Cash Flows TTM            
FCF from Operations TTM-325-306-143-189-122-159-260-278-343-352-496-468
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-47.9%-35.0%-16.0%-28.2%-41.6%-42.4%19.4%-40.2%-30.0%-23.2%-42.1%-70.2%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-28.8%-28.0%-28.8%-21.3%-24.4%-22.5%-15.6%-31.5%-36.6%-50.3%-58.5%-66.4%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Developing and commercializing therapies derived from or incorporating genome-editing technology3711   
Collaboration revenue  9131290
Grant revenue  200
Total37119151290


Price Behavior

CRSP Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta2.262.972.401.181.281.48
Up Beta2.773.143.051.231.081.15
Down Beta0.013.431.750.530.891.17
Up Capture183%281%335%211%260%704%
Bmk +ve Days10223571142415
Stock +ve Days9173359116346
Down Capture386%303%169%141%139%108%
Bmk -ve Days11192754106334
Stock -ve Days12242966132402

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity22,074,375
Short Interest: % Change Since 8152025-5.3%
Average Daily Volume1,738,538
Days-to-Cover Short Interest12.70
Basic Shares Quantity87,069,690
Short % of Basic Shares25.4%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/4/2025-6.7%-7.0%-11.1%
5/6/20253.3%12.2%16.3%
2/11/20259.3%33.8%6.0%
11/5/2024-0.5%8.4%1.1%
8/5/2024-0.7%-5.5%-9.3%
5/8/20240.5%6.9%8.6%
2/21/20244.7%13.2%-7.4%
11/6/202313.6%0.8%37.9%
...
SUMMARY STATS   
# Positive151314
# Negative91110
Median Positive5.1%12.2%11.4%
Median Negative-3.4%-7.0%-11.0%
Max Positive13.6%33.8%70.8%
Max Negative-6.7%-13.0%-34.8%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025804202510-Q 6/30/2025
3312025506202510-Q 3/31/2025
12312024211202510-K 12/31/2024
93020241105202410-Q 9/30/2024
6302024805202410-Q 6/30/2024
3312024508202410-Q 3/31/2024
12312023221202410-K 12/31/2023
93020231106202310-Q 9/30/2023
6302023807202310-Q 6/30/2023
3312023508202310-Q 3/31/2023
12312022221202310-K 12/31/2022
93020221101202210-Q 9/30/2022
6302022808202210-Q 6/30/2022
3312022509202210-Q 3/31/2022
12312021215202210-K 12/31/2021
93020211103202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Treco Douglas A 8082025Buy57.0320,0001,140,6001,254,660Form
1George Simeon 7172025Buy52.036,510338,7153,625,815Form
2Greene John 2282025Buy44.857,000313,948313,948Form
3Kulkarni SamarthChief Executive Officer2212025Sell55.2018,3601,013,5649,473,896Form
4Kulkarni SamarthChief Executive Officer12042024Sell55.1015,000826,56410,003,635Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.